US FDA’s PANDA Policy Could Pose Legal Problems For Biosimilars, Attorney Says
Executive Summary
Agency’s apparent ‘intellectual exercise’ in treating pre-Hatch-Waxman ANDAs as NDAs could expose biosimilars to liability, Teva deputy general counsel notes at FDLI conference.